STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
drugs

FDA Approves Bristol Myers Squibb’s Cobenfy: A Groundbreaking Schizophrenia Treatment

byLiliana Vida
September 27, 2024
in Biotechnology, Large-Cap
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

The First New Class of Antipsychotic Drugs in 70 Years Offers Hope for Millions but Faces Pricing Challenges

In a significant advancement for the treatment of schizophrenia, the U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s (BMY) new drug, Cobenfy. This marks the first time in over seven decades that a novel class of medication has been developed to address the debilitating mental disorder, offering a new lifeline to the nearly 3 million adults in the United States living with schizophrenia. The company plans to make the twice-daily pill available by late October, with a monthly price tag of $1,850, or $22,500 annually, before insurance and rebates.

A New Hope for Schizophrenia Treatment

Schizophrenia, a chronic mental disorder that distorts a person’s thoughts, feelings, and behavior, can manifest through symptoms such as paranoia, delusions, hallucinations, and significant changes in emotion and behavior. These symptoms often lead to severe disruptions in daily life, making it difficult for individuals to work, socialize, or manage basic tasks. Typically diagnosed in late teens to early adulthood, the condition has long been in need of more effective and tolerable treatment options.

Cobenfy’s approval is seen as a major breakthrough, particularly given that only about 1.6 million schizophrenia patients in the U.S. receive treatment, and a staggering 75% of those patients discontinue their medication within the first 18 months due to inefficacy or intolerable side effects. Existing antipsychotic drugs work by directly blocking dopamine receptors in the brain, which, while effective for some, come with a host of serious side effects, including weight gain, excessive fatigue, and involuntary movements. These adverse effects often lead to patients abandoning their treatment, further complicating their condition.

A New Mechanism of Action

Cobenfy represents a departure from traditional antipsychotic treatments. Rather than directly blocking dopamine receptors, Cobenfy utilizes a dual-action mechanism involving two components: xanomeline and trospium. Xanomeline activates specific muscarinic receptors in the brain, indirectly reducing dopamine activity without the severe side effects associated with conventional antipsychotics. Trospium, on the other hand, mitigates the gastrointestinal side effects commonly linked to xanomeline, such as nausea, vomiting, and diarrhea, making the treatment more tolerable for patients.

Dr. Samit Hirawat, Chief Medical Officer of Bristol Myers Squibb, emphasized that Cobenfy’s innovative approach could significantly improve the lives of those who have struggled to find effective and manageable treatments. “The majority of these patients have already cycled through one or two of these products,” Hirawat said. “So the enthusiasm that we’re hearing from physicians is the opportunity to have a patient go onto treatment without seeing the side effects but also getting unprecedented efficacy.”

Market Potential and Economic Considerations

Cobenfy’s approval comes at a critical time for Bristol Myers Squibb, which is facing the impending loss of revenue from top-selling drugs that are approaching patent expiration. The drug, which was acquired through Bristol Myers Squibb’s $14 billion purchase of Karuna Therapeutics, is anticipated to be a significant long-term revenue driver for the company. While analysts at Guggenheim have predicted that Cobenfy could become a multi-billion dollar product, they also noted that its launch may be slow, meaning it might not substantially impact the company’s revenue until 2026 or later.

However, the high cost of Cobenfy could be a barrier to its widespread adoption. At $1,850 per month, the drug is priced comparably to other branded schizophrenia treatments, but significantly higher than generic options, such as the generic version of Abilify, which can be as low as $16 for a month’s supply. While Bristol Myers Squibb has assured that most patients, particularly those on Medicare and Medicaid, will face minimal out-of-pocket costs, the company’s Chief Commercialization Officer, Adam Lenkowsky, acknowledged that the drug’s price might limit its initial use to patients who have failed other treatments.

Future Prospects for Cobenfy

The FDA’s approval of Cobenfy is based on data from three clinical trials that demonstrated its efficacy in reducing schizophrenia symptoms compared to a placebo, as well as two longer-term studies assessing its safety and tolerability over a year. While the initial approval is for schizophrenia, Bristol Myers Squibb has ambitious plans for Cobenfy, with ongoing research into its potential applications for other conditions such as Alzheimer’s disease, bipolar mania, and autism-related irritability.

Andrew Miller, founder and former president of research and development at Karuna Therapeutics, now an advisor to Bristol Myers Squibb, expressed optimism about the long-term impact of Cobenfy. “I think there’s potentially a really transformational moment in how we treat and talk about schizophrenia,” Miller said. “The most important moment is going to be five or ten years from now when we look back and say we’ve actually made a difference.”

As the healthcare community awaits the broader implications of Cobenfy’s introduction, its approval represents a pivotal moment in the treatment of schizophrenia, offering renewed hope to millions of patients and their families.

You migth like this article:U.S. Airlines Disrupt Operations as Hurricane Helene Approaches Florida

Tags: GrowthMoversNewsStock Market
Previous Post

U.S. Airlines Disrupt Operations as Hurricane Helene Approaches Florida

Next Post

Nio’s $1.9 Billion Cash Injection Fuels Stock Surge Amid Losses

Related Posts

Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock

byLuca Blaumann
August 7, 2025
0

Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter...

Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations

byLuca Blaumann
August 6, 2025
0

Cosmetics giant sees 30% profit drop as China duties weigh on bottom line, even as revenue and product innovation remain...

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

byLuca Blaumann
August 5, 2025
0

Telehealth company maintains 2025 outlook, expands beyond GLP-1 offerings amid regulatory and partnership setbacks Hims & Hers Health (HIMS) stock...

Next Post

Nio's $1.9 Billion Cash Injection Fuels Stock Surge Amid Losses

Latest News

LegalZoom Soars as Bank of America Upgrades Rating on AI Momentum and Subscription Growth

Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock

Daxor’s New Handheld Blood Volume Analyzer Gets FDA Green Light

Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

Based on Your Interest

trading-chart-2
IT Services

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

August 4, 2025
tesla
Artificial Intelligence

Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk

August 4, 2025
evtol
Aerospace & Defense

Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

August 4, 2025

Recommended

Large-Cap

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

July 30, 2025
Aerospace & Defense

Palo Alto Networks Eyes $20B Deal for CyberArk

July 29, 2025
Ecommerece

AMD and Amazon: Two Titans Poised for Explosive Growth

July 28, 2025
Entertainment

FCC Approves $8B Paramount-Skydance Merger Amid Political Controversy

July 25, 2025
Aerospace & Defense

FAA Keeps Boeing 737 MAX Production Cap in Place Amid Ongoing Oversight

July 24, 2025
Stoxpo

Follow us on social media:

Highlights

  • LegalZoom Soars as Bank of America Upgrades Rating on AI Momentum and Subscription Growth
  • Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock
  • Daxor’s New Handheld Blood Volume Analyzer Gets FDA Green Light
  • Tariffs Dull E.l.f. Beauty’s Shine Despite Beating Expectations
  • Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

LegalZoom Soars as Bank of America Upgrades Rating on AI Momentum and Subscription Growth

August 8, 2025

Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock

August 7, 2025

Daxor’s New Handheld Blood Volume Analyzer Gets FDA Green Light

August 7, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?